Development of gemcitabine-adsorbed magnetic gelatin nanoparticles for targeted drug delivery in lung cancer
Source abstract
Abstract
Magnetic iron oxide nanoparticles (IONPs) were coated with gelatin type B by means of the two-step desolvation method. Drug loading by adsorption was studied under various conditions such as different temperature, contact time, pH, and initial gemcitabine concentration. Further, Langmuir isotherm curves were constracted and constants were calculated. According to the Langmuir isotherm, the Gibbs free energy of the adsorption process at 25°C was - 4.74 kJ/mol. On the other hand, this value at 37°C was - 7.86 kJ/mol. In vitro drug release was performed at pH levels of 5 and 7.4, with gemcitabine-loaded magnetic gelatin nanoparticles and free gemcitabine, and both the results were subsequently compared.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Dendrimers and Hyperbranched Polymers · Drug Solubulity and Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
,
References (30)
Show source-provided references
1. 10.1016/j.nano.2011.03.00910.1016/j.nano.2011.03.009 ↗
2. 10.1016/j.ijpharm.2007.06.00610.1016/j.ijpharm.2007.06.006 ↗
3. 10.1016/S0169-409X(98)00047-710.1016/S0169-409X(98)00047-7 ↗
4. Chien YW. 1992. Oral drug delivery and delivery systems. In: Y. W. Chien Eds. Novel Drug Delivery Systems New York: Marcel Dekker Inc pp. 139–196.10.1201/b14196-4 ↗
5. 10.1016/S0169-409X(98)00041-610.1016/S0169-409X(98)00041-6 ↗
6. 10.1016/j.ejpb.2011.01.00810.1016/j.ejpb.2011.01.008 ↗
7. 10.1088/1742-6596/187/1/01203610.1088/1742-6596/187/1/012036 ↗
8. Gabr Y, Assem N, Michael A, Fahmy L. 1996. Evaluation studies on oxypolygelatin and degraded gelatin as plasma volume expander Arzneimittelforschung. 46:763–766.
9. 10.1016/j.msec.2008.01.00110.1016/j.msec.2008.01.001 ↗
10. 10.1080/0265204070173769710.1080/02652040701737697 ↗
11. 10.1016/j.ijpharm.2008.08.02010.1016/j.ijpharm.2008.08.020 ↗
12. Gennaro AR. 2006. Remington: The Science and Practice of Pharmacy. Part 5: Pharmaceutical Manufacturing/Extended-Release and Targeted Drug Delivery Systems, The New Drug Approval Process and Clinical Trial Design. In: Philadelphia, PA: Lippincott Williams Wilkins, pp. 939–965.
13. 10.1016/j.foodhyd.2011.02.00710.1016/j.foodhyd.2011.02.007 ↗
14. 10.1016/j.urolonc.2007.03.01510.1016/j.urolonc.2007.03.015 ↗
15. 10.1080/10826068.2012.71293710.1080/10826068.2012.712937 ↗
16. 10.1016/j.bcp.2011.01.01610.1016/j.bcp.2011.01.016 ↗
17. 10.1016/j.lwt.2009.06.01210.1016/j.lwt.2009.06.012 ↗
18. 10.2174/187447101080101003010.2174/1874471010801010030 ↗
19. 10.1016/S0378-5173(97)00149-X10.1016/S0378-5173(97)00149-X ↗
20. Lippincort R. 1997. American Joint Commitee on Cancer (AJCC), In: Cancer Staging Manual, 5th edn. , Lippincott Williams & Wilkins: Philadelphia, pp. 127–37.
21. 10.1006/jsre.2000.603010.1006/jsre.2000.6030 ↗
22. 10.1016/j.ijpharm.2012.12.04810.1016/j.ijpharm.2012.12.048 ↗
23. 10.1016/j.jhazmat.2007.04.11710.1016/j.jhazmat.2007.04.117 ↗
24. 10.1016/j.nano.2008.03.00710.1016/j.nano.2008.03.007 ↗
25. 10.1016/j.ejpb.2010.04.00810.1016/j.ejpb.2010.04.008 ↗
26. 10.1016/0378-5173(81)90100-910.1016/0378-5173(81)90100-9 ↗
27. 10.1016/j.yexmp.2008.12.00410.1016/j.yexmp.2008.12.004 ↗
28. Tomlinson E, Davis S. 1986. Site Spesific Drug Delivery. Chichester: Wiley, New York: Plenum press, p. 93.
29. 10.3109/21691401.2012.74586310.3109/21691401.2012.745863 ↗
30. 10.1007/s11095-007-9410-510.1007/s11095-007-9410-5 ↗